Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 09, 2026, titled "Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has received final approval from the U.S. FDA for Progesterone Vaginal Inserts, 100 mg. The product is bioequivalent and therapeutically equivalent to Ferring Pharmaceuticals' Endometrin® Vaginal Inserts. The drug will be distributed in the U.S. market by Glenmark Pharmaceuticals Inc., USA. According to IQVIA sales data, the U.S. market for this product achieved annual sales of approximately $59.2 million for the 12-month period ending February 2026. This approval adds to Glenmark's women's healthcare portfolio and expands their presence in the U.S. generics market.
This FDA approval opens a new revenue opportunity for Glenmark in the U.S. women's health segment. With a total addressable market of $59.2 million, this product launch could contribute positively to Glenmark's U.S. revenues, making it a constructive development for shareholders.